   
Aspreva Lupus Management Study
ALMS, the Aspreva Lupus Management Study, is a worldwide research study, sponsored by Aspreva Pharmaceuticals.
ALMS is part of the Roche-Aspreva
Collaboration Agreement, which will evaluate the effect of a study medication in the initial
treatment of Lupus Nephritis (induction phase) and will assess how well it
maintains this effect over longer periods (maintenance phase), when compared to
the current standard treatments. The safety of the study medication in the long-term treatment of
lupus nephritis will also be assessed.
The Aspreva Lupus Management Study is one of the largest phase III studies
conducted in lupus nephritis. The first patient in this study was treated in July 2005. The global study aims to enrol
over 350 patients in clinics worldwide.
Each of these sites will be using ADS-Limathon's BLIPS™
Version 4.0 as a tool to measure and record the effect of the study
medication on the enrolled patients. This section of the ADS-Limathon website
provides software support to the clinicians and clinical research associates.
ADS-Limathon would like to acknowledge Aspreva Pharmaceuticals sponsorship
and collaboration in the development of BLIPS Version 4.0 and wish them every
success with the study.
Please browse the ALMS website for
more information about the study.
| 
